While European indices face pressure, underlying business optimism is at a 20-month high. We spotlight three under-the-radar companies—Premier Energy, BW Offshore, and RVRC Holding—whose fundamentals suggest they are well-positioned to navigate the current climate and deliver value.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
With economic crosswinds buffeting regional markets, income-focused investors are increasingly looking to dividend-paying equities in Asia to anchor their portfolios. We examine three prominent names offering compelling yields.
U.S. stocks advanced cautiously Monday as investors braced for a wave of corporate earnings reports, while crude oil prices tumbled sharply. The focus remains on key tech results and evolving geopolitical developments affecting global trade and energy markets.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
A powerful but uncommon shift in market leadership is underway as small-caps, energy, and value stocks drive gains. While a sign of health, historical parallels to similar 'breadth' events often coincided with economic stress.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
Investment firm Curreen Capital posted strong 2025 results, crediting its focus on undervalued 'ugly duckling' stocks. The fund's latest letter spotlights VF Corporation (VFC), the embattled owner of Vans and The North Face, as a potential turnaround play despite its shares falling over 20% in the past year.
After a punishing multi-year slump, materials stocks are showing signs of life in 2026. Dow and LyondellBasell, offering yields of 5% and 10.9% respectively, present a high-risk, high-reward proposition for income investors betting on a sector recovery.
As the TSX rides a wave of broad-based earnings optimism, a closer look reveals smaller companies, often miscategorized as 'penny stocks', that combine financial resilience with clear growth trajectories. We examine three such firms with market caps up to CA$700 million.
A combination of moderating inflation and resilient corporate earnings is setting the stage for sustained stability in stock markets, with the recent rally now encompassing small-caps, value stocks, and multiple sectors.
Analyst Joe Laetsch raises HF Sinclair's price target, highlighting favorable crude differentials and a recent $38 million acquisition aimed at expanding its lubricants business, as the refiner lands on a list of top low-risk dividend stocks.
Amid a mixed market landscape, corporate insiders are placing significant bets on select small-cap stocks. We analyze three companies where recent insider buying and strategic moves signal potential value, despite broader economic headwinds.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
After a punishing year for many restaurant stocks, a seismic shift is underway. As inflation-weary diners become more selective, value and experience are trumping category labels, driving a surprising resurgence in casual dining while challenging the fast-casual model.
While small-cap stocks offer significant growth potential, their volatility demands careful selection. We analyze one standout and two struggling companies in the Russell 2000 index this week.
Amid a cautiously recovering Eurozone economy, dividend-paying stocks are gaining attention from investors seeking reliable income and a buffer against market volatility. We analyze three standout European companies offering compelling yield and value.
